Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Gefitinib in EGFR-mutated NSCLC
NCT02976116Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2016
- Primary completion
- Jun 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in non-small cell lung cancer (NSCLC), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Objective Response Rate at 1 year and Safety and tolerability. Started Dec 2016; status: completed.
02
Drugs
fruquintinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02976116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976116.